



TEGSEDI is a registered trademark of Akcea Therapeutics, Inc., discovered and developed by Ionis Pharmaceuticals and distributed by Sobli, Inc.
© 2024, Akcea Therapeutics, Inc. All rights reserved. REF-11441 XX/24

TEGSEDI® PATIENT WALLET CARD

Carry this card with you at all times. **SHOW THIS CARD** if you go to the emergency room or see any healthcare provider.

Tell any healthcare provider that sees you that you are being treated with TEGSEDI.

Prescriber's name (first & last):

Prescriber phone #:



Patient information

TEGSEDI may cause side effects that are severe or life threatening at any time during treatment.

Call your doctor or go to the emergency room RIGHT AWAY if you have any of these symptoms:

- Unusual bruising or a rash of tiny reddish-purple spots, often on the lower legs
- Bleeding from skin cuts that does not stop or oozes
- Bleeding from your gums or nose
- Blood in urine or stools
- Bleeding into the whites of your eyes
- Sudden severe headaches or neck stiffness
- Vomiting blood or coughing up blood
- Abnormal or heavy menstrual periods
- Puffiness or swelling in your face, feet, or hands
- New onset or worsening shortness of breath and coughing
- Blood in your urine or brown urine
- Foamy urine (proteinuria)
- Passing less urine than usual

Important information for healthcare providers

This patient is receiving TEGSEDI for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

TEGSEDI has a risk of serious bleeding with severe thrombocytopenia and a risk of glomerulonephritis. Patients treated with TEGSEDI are being regularly monitored for these risks via the following lab results: platelets, estimated glomerular filtration rate (eGFR), urinalysis, and urine protein to creatinine ratio (UPCR).